Dublin, April 12, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" to their offering.
This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described.
A section on drug abuse describes methods of detection of performance-enhancing drugs. TDM market is analyzed from 2015 to 2025 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2015 to 2025 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed.
The report contains profiles of 27 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 18 tables, 6 figures and 190 selected references from literature.
Who should read this report?
- Biotechnology companies developing assays and equipment for drug monitoring.
- Reference laboratories providing drug monitoring services.
- Pharmaceutical companies interested in companion tests for monitoring their drugs.
- Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine.
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies for TDM
3. Drug Monitoring Instruments
4. Applications of TDM
5. Drugs Requiring Monitoring
6. Monitoring of Biological Therapies
7. Monitoring of Drug Abuse
8. Markets for TDM
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/d48q5h/therapeutic_drug
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Discovery


OpenAI Addresses Security Vulnerability in macOS App Certification Process
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 



